MORRISTOWN, N.J., July 27 /PRNewswire-FirstCall/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded
pharmaceuticals, announced that effective today Mark W. Durand, Senior Vice
President and Chief Financial Officer, has taken a leave of absence from the
Company for health reasons. Paul Bisaro, President and Chief Executive
Officer of Watson, announced that R. Todd Joyce, Vice President, Corporate
Controller and Treasurer, will serve as Acting Principal Financial Officer,
effective immediately.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., (NYSE: WPI) is a global leader in the
development and distribution of pharmaceuticals with a broad portfolio of
generic products and a specialized portfolio of branded pharmaceuticals
focused on Urology, Gynecology and Nephrology (Medical).
For press releases and other company information, visit the Watson website
at http://www.watson.com.
Forward-Looking Statement
Any statements contained in this press release that refer to future events
or other non-historical facts are forward-looking statements that reflect
Watson's current perspective of existing trends and information as of the date
of this release. Except as expressly required by law, Watson disclaims any
intent or obligation to update these forward-looking statements. Actual
results may differ materially from Watson's current expectations depending
upon a number of factors affecting Watson's business. These factors include,
among others, the risks and uncertainties detailed in Watson's periodic public
filings with the Securities and Exchange Commission, including but not limited
to Watson's Annual Report on Form 10-K for the year ended December 31, 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)
SOURCE Watson Pharmaceuticals, Inc.
-0- 07/27/2009
/CONTACT: Patty Eisenhaur of Watson Pharmaceuticals, Inc.,
+1-951-493-5611/
/Photo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO
http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com/
/Web Site: http://www.watson.com /
(WPI)
CO: Watson Pharmaceuticals, Inc.
ST: New Jersey
IN: HEA MTC PHA
SU: PER
PR
-- LA52501 --
5651 07/27/2009 16:40 EDT http://www.prnewswire.com
